CO2018009124A2 - Análogos de cannabidiol biológicamente activos - Google Patents
Análogos de cannabidiol biológicamente activosInfo
- Publication number
- CO2018009124A2 CO2018009124A2 CONC2018/0009124A CO2018009124A CO2018009124A2 CO 2018009124 A2 CO2018009124 A2 CO 2018009124A2 CO 2018009124 A CO2018009124 A CO 2018009124A CO 2018009124 A2 CO2018009124 A2 CO 2018009124A2
- Authority
- CO
- Colombia
- Prior art keywords
- analogues
- biologically active
- dicarboxylic acid
- acid
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C69/40—Succinic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C69/42—Glutaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Resumen Análogos de cannabidiol biológicamente activos que comprenden un compuesto de fórmula en donde uno de R1 o R2 o ambos es/son el residuo de un resto formado por la reacción de un grupo amino del éster de aminoácido de R1 o R2 o ambos con un ácido dicarboxílico o un derivado de ácido dicarboxílico y el otro R1 o R2 (en el caso del mono) es el residuo de un ácido dicarboxílico o derivado de ácido dicarboxílico o Hidrógeno (H), (es decir, no derivatizado), y sus sales. Estos análogos de CBD son útiles en el manejo del dolor en oncología y otros entornos clínicos en los que se presenta neuropatía. Además, estos análogos de CBD son útiles para bloquear las propiedades adictivas de los opiáceos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662289184P | 2016-01-29 | 2016-01-29 | |
PCT/US2017/015366 WO2017132526A1 (en) | 2016-01-29 | 2017-01-27 | Biologically active cannabidiol analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018009124A2 true CO2018009124A2 (es) | 2018-09-10 |
Family
ID=59399025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0009124A CO2018009124A2 (es) | 2016-01-29 | 2018-08-29 | Análogos de cannabidiol biológicamente activos |
Country Status (13)
Country | Link |
---|---|
US (6) | US10709681B2 (es) |
EP (1) | EP3407973B1 (es) |
JP (1) | JP6676176B2 (es) |
KR (1) | KR102202133B1 (es) |
AU (1) | AU2017212651B2 (es) |
BR (1) | BR112018015570A2 (es) |
CA (1) | CA3013037C (es) |
CO (1) | CO2018009124A2 (es) |
ES (1) | ES2960825T3 (es) |
IL (1) | IL260817B (es) |
NZ (1) | NZ745595A (es) |
WO (1) | WO2017132526A1 (es) |
ZA (1) | ZA201805747B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
CA3013037C (en) * | 2016-01-29 | 2021-10-05 | Mahmoud A. Elsohly | Biologically active cannabidiol analogs |
WO2018096504A1 (en) * | 2016-11-28 | 2018-05-31 | Kalytera Therapeutics, Inc | Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs |
CN107669744A (zh) * | 2017-11-30 | 2018-02-09 | 云南汉木森生物科技有限责任公司 | 含有工业大麻的药包 |
EP3876907A4 (en) * | 2018-11-07 | 2022-08-10 | Columbia Care LLC | CANNABINOID SUPPOSITORY FORMULATIONS |
WO2021000053A1 (en) * | 2019-07-04 | 2021-01-07 | Canopy Growth Corporation | Cannabinoid derivatives |
EP4034100A4 (en) | 2019-09-26 | 2023-10-11 | Firstlight Pharmaceuticals LLC | CANNABINOID PRODRUG COMPOUNDS |
CN112831091B (zh) * | 2019-11-25 | 2023-03-21 | 星欧光学股份有限公司 | 塑化剂及塑胶产品 |
WO2021113083A1 (en) | 2019-12-06 | 2021-06-10 | JLABS Beauty LLC | Topical compositions containing rose oil and cannabidiol and methods of making and using the same |
US11396500B2 (en) * | 2019-12-18 | 2022-07-26 | Dieu Cam Vuong | Heat and oxidation resistant Δ9 tetrahydrocannobinol (THC) and cannabiniol (CBD) compound and method of manufacturing the same |
CN113087741B (zh) * | 2020-01-08 | 2023-04-28 | 成都百裕制药股份有限公司 | 大麻二酚衍生物及其制备方法和在医药上的应用 |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US20230405024A1 (en) * | 2020-03-13 | 2023-12-21 | Michael Milane | Novel nano-formulation of cannabidiol (cbd) and other cannabinoids for treatment of ocular disorders |
CA3179442A1 (en) | 2020-05-22 | 2021-11-25 | Brian Warrington | Compositions for treating acne and dermatological conditions |
WO2022111587A1 (zh) * | 2020-11-25 | 2022-06-02 | 成都百裕制药股份有限公司 | 大麻素类化合物的制备方法 |
CN116253700A (zh) * | 2021-12-10 | 2023-06-13 | 德义制药有限公司 | 一种大麻二酚衍生物及其制备方法和应用 |
CN116253671A (zh) * | 2021-12-10 | 2023-06-13 | 德义制药有限公司 | 一种大麻二酚衍生物及其制备方法和应用 |
WO2023235386A1 (en) * | 2022-05-31 | 2023-12-07 | Trait Biosciences, Inc. | Water-soluble cannabinoid prodrugs compositions and methods of synthesizing the same |
CN116983264B (zh) * | 2023-09-28 | 2023-12-22 | 中国农业科学院农产品加工研究所 | 一种二氢大麻二酚二苯甲酸酯的包埋体系及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3728360A (en) | 1971-08-31 | 1973-04-17 | Little Inc A | Ester derivatives of tetrahydrocannabinol |
WO2008107879A1 (en) * | 2007-03-05 | 2008-09-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel cannabidiol derivatives and their use as anti-inflammatory agents |
US8293786B2 (en) * | 2007-07-30 | 2012-10-23 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
SI2215071T1 (sl) | 2007-11-30 | 2015-12-31 | Zynerba Pharmaceuticals, Inc. | Predzdravila tetrahidrokanabinola, sestavki, ki obsegajo predzdravila tetrahidrokanabinola in postopki njihove uporabe |
HUE032158T2 (en) * | 2008-10-31 | 2017-09-28 | Univ Mississippi | Process for the preparation of delta9-THC amino acid esters |
PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
WO2014134127A1 (en) | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
CA3013037C (en) * | 2016-01-29 | 2021-10-05 | Mahmoud A. Elsohly | Biologically active cannabidiol analogs |
WO2017147202A1 (en) * | 2016-02-22 | 2017-08-31 | West Pharmaceutical Services, Inc. | Drug delivery device state recognition |
EP3442953A1 (en) * | 2016-04-15 | 2019-02-20 | Teewinot Technologies Limited | Biosynthesis of cannabinoid prodrugs |
US20170362195A1 (en) * | 2016-06-16 | 2017-12-21 | Full Spectrum Laboratories Ltd | Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use |
WO2018096504A1 (en) * | 2016-11-28 | 2018-05-31 | Kalytera Therapeutics, Inc | Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs |
-
2017
- 2017-01-27 CA CA3013037A patent/CA3013037C/en active Active
- 2017-01-27 BR BR112018015570A patent/BR112018015570A2/pt active Search and Examination
- 2017-01-27 AU AU2017212651A patent/AU2017212651B2/en active Active
- 2017-01-27 JP JP2018539351A patent/JP6676176B2/ja active Active
- 2017-01-27 US US16/073,766 patent/US10709681B2/en active Active
- 2017-01-27 ES ES17744984T patent/ES2960825T3/es active Active
- 2017-01-27 WO PCT/US2017/015366 patent/WO2017132526A1/en active Application Filing
- 2017-01-27 KR KR1020187024768A patent/KR102202133B1/ko active IP Right Grant
- 2017-01-27 NZ NZ745595A patent/NZ745595A/en unknown
- 2017-01-27 EP EP17744984.0A patent/EP3407973B1/en active Active
-
2018
- 2018-07-26 IL IL260817A patent/IL260817B/en unknown
- 2018-08-28 ZA ZA2018/05747A patent/ZA201805747B/en unknown
- 2018-08-29 CO CONC2018/0009124A patent/CO2018009124A2/es unknown
-
2020
- 2020-06-09 US US16/896,242 patent/US11596617B2/en active Active
- 2020-06-09 US US16/896,240 patent/US11337951B2/en active Active
- 2020-06-09 US US16/896,239 patent/US11337950B2/en active Active
- 2020-06-09 US US16/896,241 patent/US11337952B2/en active Active
- 2020-06-09 US US16/896,243 patent/US11344525B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3013037A1 (en) | 2017-08-03 |
US11337952B2 (en) | 2022-05-24 |
US20200297687A1 (en) | 2020-09-24 |
US10709681B2 (en) | 2020-07-14 |
NZ745595A (en) | 2019-12-20 |
JP2019509983A (ja) | 2019-04-11 |
US20190031601A1 (en) | 2019-01-31 |
EP3407973B1 (en) | 2023-07-26 |
KR102202133B1 (ko) | 2021-01-14 |
US11337950B2 (en) | 2022-05-24 |
ES2960825T3 (es) | 2024-03-06 |
US11344525B2 (en) | 2022-05-31 |
US20200306217A1 (en) | 2020-10-01 |
ZA201805747B (en) | 2019-05-29 |
US20200297688A1 (en) | 2020-09-24 |
JP6676176B2 (ja) | 2020-04-08 |
IL260817B (en) | 2021-08-31 |
US11337951B2 (en) | 2022-05-24 |
EP3407973A1 (en) | 2018-12-05 |
CA3013037C (en) | 2021-10-05 |
AU2017212651B2 (en) | 2020-01-23 |
BR112018015570A2 (pt) | 2018-12-26 |
WO2017132526A1 (en) | 2017-08-03 |
AU2017212651A1 (en) | 2018-09-13 |
KR20180120683A (ko) | 2018-11-06 |
US20210030708A1 (en) | 2021-02-04 |
US11596617B2 (en) | 2023-03-07 |
EP3407973A4 (en) | 2019-09-11 |
US20200383944A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018009124A2 (es) | Análogos de cannabidiol biológicamente activos | |
CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
UY37302A (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
DOP2021000088A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
CR20170438A (es) | Desacetoxitubulisina h y análogos de esta | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
MX2020003883A (es) | Composiciones que contienen derivados de acido benzoico o acido furoico y uso de los derivados para estabilidad de emulsion y de espuma. | |
AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
CL2022003047A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
CO2022001814A2 (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
CL2022003041A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
RU2009128593A (ru) | Средства борьбы с паразитами животных | |
CL2022000835A1 (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
BR112022017283A2 (pt) | Cristalização de 2?-fl | |
AR106958A1 (es) | Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne | |
AR081804A1 (es) | Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades | |
AR070737A1 (es) | Proceso para la elaboracion de (fenilsulfanilfenil) piperidinas | |
CO2022010011A2 (es) | Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo | |
AR107310A1 (es) | Inhibidores de tetrahidrocarbazol de receptores sirt1 | |
AR107163A1 (es) | Inhibidores de quinasa |